TOP TEN perturbations for 38469_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38469_at
Selected probe(set): 203824_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38469_at (203824_at) across 6674 perturbations tested by GENEVESTIGATOR:
ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-9.329862Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-9.184165Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary carcinoma, NOS of the ovary (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
Barrett's esophagus study 3 / esophageal squamous cell carcinoma study 1
Relative Expression (log2-ratio):9.072659Number of Samples:17 / 8
| Experimental | Barrett's esophagus study 3 |
| Esophageal epithelium samples from areas with Barrett's esophagus metaplasia which were recovered by laser capture microdissection. | |
| Control | esophageal squamous cell carcinoma study 1 |
| Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy. |
Barrett's esophagus study 3 / normal esophageal epithelium sample
Relative Expression (log2-ratio):8.782684Number of Samples:17 / 18
| Experimental | Barrett's esophagus study 3 |
| Esophageal epithelium samples from areas with Barrett's esophagus metaplasia which were recovered by laser capture microdissection. | |
| Control | normal esophageal epithelium sample |
| Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy. |
esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / esophagus cancer study 1 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-8.7164345Number of Samples:3 / 8
| Experimental | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). | |
| Control | esophagus cancer study 1 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the oesophagus (subcutaneously implanted). |
MALT lymphoma study 1 / normal spleen tissue
Relative Expression (log2-ratio):8.406033Number of Samples:8 / 6
| Experimental | MALT lymphoma study 1 |
| Human t(11;18)-negative mucosa-associated lymphoid tissue (MALT) lymphoma cells. | |
| Control | normal spleen tissue |
| Normal human spleen tissue sample. |
esophageal squamous cell carcinoma study 1 / esophageal adenocarcinoma study 1
Relative Expression (log2-ratio):-8.157557Number of Samples:8 / 20
| Experimental | esophageal squamous cell carcinoma study 1 |
| Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy. | |
| Control | esophageal adenocarcinoma study 1 |
| Esophageal adenocarcinoma (EAC) samples of affected epithelium recovered by laser capture microdissection technique. |
esophageal adenocarcinoma study 1 / normal esophageal epithelium sample
Relative Expression (log2-ratio):7.8675823Number of Samples:20 / 18
| Experimental | esophageal adenocarcinoma study 1 |
| Esophageal adenocarcinoma (EAC) samples of affected epithelium recovered by laser capture microdissection technique. | |
| Control | normal esophageal epithelium sample |
| Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy. |
pancreatic islet study 3 (re-differentiated; PPRF; 4d) / normal pancreatic islet sample
Relative Expression (log2-ratio):-7.366343Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 4d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 4 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
pancreatic islet study 3 (re-differentiated; PPRF; 6d) / normal pancreatic islet sample
Relative Expression (log2-ratio):-7.232774Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 6d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 6 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0 ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |